Tanvex BioPharma, Inc. (TPE: 6541)
Taiwan
· Delayed Price · Currency is TWD 68.50
+3.40 (5.22%)
Jan 20, 2025, 1:30 PM CST
Tanvex BioPharma Cash Flow Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
| Net Income | -1,621 | -2,137 | -1,641 | -1,543 | -2,104 | -2,274 | Upgrade
|
| Depreciation & Amortization | 298.42 | 323.59 | 280.01 | 241.43 | 215.83 | 209.48 | Upgrade
|
| Other Amortization | 1.29 | 1.24 | 1.55 | 2.15 | 4.58 | 6.49 | Upgrade
|
| Loss (Gain) From Sale of Assets | 1.83 | 2.87 | 7.21 | 0.94 | 0.27 | 0.14 | Upgrade
|
| Asset Writedown & Restructuring Costs | 8.67 | 8.67 | - | - | - | - | Upgrade
|
| Stock-Based Compensation | -9.21 | 326.61 | 67.55 | 52.95 | 80.36 | 155.72 | Upgrade
|
| Other Operating Activities | 18.59 | 0.32 | - | -90.2 | 0.63 | 13.99 | Upgrade
|
| Change in Accounts Receivable | -5.58 | -9.06 | 2.19 | -2.52 | -0.72 | -0.88 | Upgrade
|
| Change in Inventory | 2.3 | 62.56 | -80.51 | -40.25 | 2.12 | -23.63 | Upgrade
|
| Change in Accounts Payable | -49.98 | 33.41 | -15.59 | -66.97 | 32.43 | 12.13 | Upgrade
|
| Change in Unearned Revenue | 0.2 | -10.93 | 28.07 | - | - | - | Upgrade
|
| Change in Other Net Operating Assets | 71.86 | -35.98 | 16.82 | 58.67 | -18.88 | 2.14 | Upgrade
|
| Operating Cash Flow | -1,283 | -1,434 | -1,334 | -1,387 | -1,788 | -1,899 | Upgrade
|
| Capital Expenditures | -97.27 | -71.02 | -93.5 | -29.82 | -66.03 | -89.1 | Upgrade
|
| Sale of Property, Plant & Equipment | 0.52 | 6.33 | 1.82 | 6.7 | 0.17 | - | Upgrade
|
| Sale (Purchase) of Intangibles | -1.67 | -0.32 | -2.58 | -0.52 | -1.47 | -4.5 | Upgrade
|
| Investment in Securities | - | - | - | - | -193.87 | - | Upgrade
|
| Other Investing Activities | 2.33 | -18.57 | -3.09 | -1.04 | 17.9 | 1,913 | Upgrade
|
| Investing Cash Flow | -96.08 | -83.57 | -97.35 | -24.68 | -243.3 | 1,819 | Upgrade
|
| Long-Term Debt Issued | - | - | - | - | 94.87 | - | Upgrade
|
| Long-Term Debt Repaid | - | -127.67 | -130.53 | -93.11 | -67.76 | -68.18 | Upgrade
|
| Net Debt Issued (Repaid) | -161.33 | -127.67 | -130.53 | -93.11 | 27.11 | -68.18 | Upgrade
|
| Issuance of Common Stock | 1,443 | 1,207 | 7.24 | 1,690 | 1,703 | 982.34 | Upgrade
|
| Financing Cash Flow | 1,282 | 1,080 | -123.29 | 1,597 | 1,730 | 914.16 | Upgrade
|
| Foreign Exchange Rate Adjustments | -34.55 | 32.36 | 117.75 | -31.25 | -58.41 | -38.03 | Upgrade
|
| Net Cash Flow | -131.69 | -405.48 | -1,437 | 154.37 | -358.84 | 796.75 | Upgrade
|
| Free Cash Flow | -1,380 | -1,505 | -1,427 | -1,417 | -1,854 | -1,988 | Upgrade
|
| Free Cash Flow Margin | -3370.12% | -2450.42% | -6370.97% | -26208.75% | -617884.67% | - | Upgrade
|
| Free Cash Flow Per Share | -9.35 | -11.67 | -12.14 | -13.05 | -20.71 | -24.27 | Upgrade
|
| Cash Interest Paid | 57.56 | 57.38 | 54.72 | 45.81 | 17.96 | 15.58 | Upgrade
|
| Cash Income Tax Paid | 0.75 | 0.88 | 0.02 | 0.02 | 0.02 | 0.03 | Upgrade
|
| Levered Free Cash Flow | -785.69 | -713.06 | -844.23 | -819.13 | -1,075 | -1,205 | Upgrade
|
| Unlevered Free Cash Flow | -749.72 | -677.19 | -810.03 | -790.24 | -1,063 | -1,196 | Upgrade
|
| Change in Net Working Capital | -41.18 | -55.68 | 59.61 | 56.93 | -15.83 | 18.57 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.